United States Isocitrate Dehydrogenase Inhibitors: Combination Therapy Trends in Oncology | Major Companies - Merck KGaA, Adooq Bioscience LLC, Rigel Pharmaceuticals Inc.

Market Size and Forecast:

Global Isocitrate Dehydrogenase Inhibitors Market is expected to reach growth at a Significant CAGR during the forecast period 2025-2032.

The Isocitrate Dehydrogenase Inhibitors Market Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/isocitrate-dehydrogenase-inhibitors-market?ca

Isocitrate dehydrogenase (IDH) inhibitors are targeted cancer therapies designed to block mutated IDH1 and IDH2 enzymes, which produce oncometabolites that drive tumor growth. These inhibitors help restore normal cellular differentiation and are primarily used in treating cancers such as acute myeloid leukemia (AML) and glioma. Their growing clinical adoption reflects the increasing focus on precision oncology and mutation-specific treatments.

Recent Key Developments of United States and Japan:

USA

September 19, 2025: Results from a Phase 3 trial for the dual IDH1/2 inhibitor vorasidenib were highlighted following its FDA approval status for adults and children with IDH1/2-mutant Grade 2 astrocytoma or oligodendroglioma, reinforcing its role as the first targeted oral therapy for this brain tumor type.

August 8, 2025: The FDA granted Accelerated Approval to zongertinib (Hernexeos), a non-IDH inhibitor, for NSCLC, but this approval is part of a broader regulatory trend favoring targeted oncology therapies that relies on genetic screening, which is rapidly expanding the market for all biomarker-driven drugs, including IDH inhibitors.

Japan

September 11, 2025: The Phase 1b/2 study for vorasidenib in combination with temozolomide (TMZ) in IDH-mutant glioma was updated and verified on ClinicalTrials.gov, indicating continued progress in clinical development for this brain-penetrant dual inhibitor in Japan.

Ongoing Trend (Jul-Sept 2025): The Japanese oncology market continued to see a strong focus on next-generation IDH inhibitors like HMPL-306 (a dual IDH1/2 inhibitor), which is in Phase 1 trials for relapsed/refractory IDH-mutant AML, seeking to overcome resistance to first-generation treatments.

List of the Key Players in the Isocitrate Dehydrogenase Inhibitors Market Market:

Merck KGaA
Adooq Bioscience LLC
Agios Pharmaceuticals Inc
Rigel Pharmaceuticals Inc.
Servier
Celgene Corporation
Bristol Myers Squibb
Philogen SpA

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/isocitrate-dehydrogenase-inhibitors-market?ca

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Segments Covered in the Isocitrate Dehydrogenase Inhibitors Market Market:

➥ By Type: IDH1 Inhibitor, IDH2 Inhibitor, Others
➥ By Application: Acute Myeloid Leukemia, Cholangiocarcinoma, Others
➥ By Route of Administration: Oral, Parenteral

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=isocitrate-dehydrogenase-inhibitors-market?ca

Chapter Outline

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Isocitrate Dehydrogenase Inhibitors Market Market market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Isocitrate Dehydrogenase Inhibitors Market Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The Global Isocitrate Dehydrogenase Inhibitors Market Market leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Isocitrate Dehydrogenase Inhibitors Market Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Isocitrate Dehydrogenase Inhibitors Market Market in 2025?
◆ What is the projected growth rate of the Isocitrate Dehydrogenase Inhibitors Market Market through 2033?
◆ Who are the key players in the Isocitrate Dehydrogenase Inhibitors Market Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.